+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Octreotide Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

Octreotide Market Size, Forecast, and Market Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
From
From
JARDIANCE Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

JARDIANCE Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
FARXIGA Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

FARXIGA Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
Empagliflozin Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

Empagliflozin Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Product Thumbnail Image

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist

  • Clinical Trials
  • June 2022
  • 65 Pages
  • Global
From
From
From
Hunter Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hunter Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Metabolic Acidosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Metabolic Acidosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Osteoporosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Osteoporosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Dementia with Diabetes - Epidemiology Forecast to 2032 - Product Thumbnail Image

Dementia with Diabetes - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Pompe Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Pompe Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Cushing's Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Cushing's Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Diabetic Retinopathy - Epidemiology Forecast to 2032 - Product Thumbnail Image

Diabetic Retinopathy - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more